KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Steris (STE) Research & Development (2018 - 2025)

Steris has reported Research & Development over the past 8 years, most recently at $29.5 million for Q4 2025.

  • Quarterly results put Research & Development at $29.5 million for Q4 2025, up 7.66% from a year ago — trailing twelve months through Dec 2025 was $111.7 million (up 3.99% YoY), and the annual figure for FY2025 was $107.6 million, up 3.83%.
  • Research & Development for Q4 2025 was $29.5 million at Steris, up from $28.2 million in the prior quarter.
  • Over the last five years, Research & Development for STE hit a ceiling of $29.5 million in Q4 2025 and a floor of $17.5 million in Q1 2021.
  • Median Research & Development over the past 5 years was $25.4 million (2022), compared with a mean of $24.9 million.
  • Biggest five-year swings in Research & Development: surged 51.02% in 2021 and later fell 6.17% in 2023.
  • Steris' Research & Development stood at $24.8 million in 2021, then grew by 2.78% to $25.5 million in 2022, then dropped by 1.02% to $25.3 million in 2023, then rose by 8.49% to $27.4 million in 2024, then increased by 7.66% to $29.5 million in 2025.
  • The last three reported values for Research & Development were $29.5 million (Q4 2025), $28.2 million (Q3 2025), and $26.4 million (Q2 2025) per Business Quant data.